Helius Medical Technologies has initiated a Phase III clinical trial to investigate the safety and effectiveness of the portable neuromodulation stimulator (PoNS) 4.0 device to treat balance disorder in patients with mild-to-moderate traumatic brain injury (mTBI).

Conducted in collaboration with the US Army Medical Research and Materiel Command (USAMRMC), the trial aims to serve as the basis to seek Canadian and US marketing approvals of the device that is designed to induce neuromodulation by stimulating the cranial nerves found in the tongue.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

During the trial, the team will study the safety and effectiveness of the PoNS for cranial nerve noninvasive neuromodulation (CN-NINM) training in subjects with a chronic balance deficit due to mTBI.

Featuring 120 subjects, the seven-month double-blind, randomised, sham-controlled study is being conducted at the Montreal Neurofeedback Center, the Oregon Health & Science University Center for Regenerative Medicine, and the Orlando Regional Medical Center.

Helius CEO Philippe Deschamps said: "Traumatic Brain Injury (TBI) remains a serious public health problem both for the military and civilian populations for which there have been almost no new developments in treatment since the introduction of physical therapy several decades ago.

See Also:

"We are excited to begin the clinical trials for the PoNS device as a potential treatment for symptoms of TBI in our wounded warriors."

"There is also a large population of TBI patients who develop chronic symptoms, for which traditional physical therapy has proven ineffective."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

USAMRMC acquisition principal assistant Dr Kenneth Bertram said: "We are excited to begin the clinical trials for the PoNS device as a potential treatment for symptoms of TBI in our wounded warriors."

The Montreal Neurofeedback Center will be the first site to begin recruitment and screening of the subjects. The primary endpoint at five weeks is improvement in chronic balance deficit as analysed by the Sensory Organization Test.

The study seeks to demonstrate that CN-NINM, which combines the PoNS device with a unique physiotherapy regiment, may provide new rehabilitative opportunities for patients suffering from chronic symptoms.

The US Department of Defense has reported approximately 200,000 cases of TBI in soldiers between 2000 and June 2010.